Sylvia Heink

Sylvia Heink

Auto-generated profile, based on publicly available information

Sylvia Heink

Institute for Experimental Neuroimmunology, Technical University of Munich School of Medicine, Munich, Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2007 in Nature Immunology
Verified
Journal Article
Closed access
ABAnne Brüstle
Anne Brüstle
SHSylvia Heink
Sylvia Heink
MHMagdalena Huber
Magdalena Huber
CRChristine Rosenplänter
Christine Rosenplänter
CSChristine Stadelmann
Christine Stadelmann
MLMichael Lohoff
Michael Lohoff

4 May 2018 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
CGChristoph Garbers
Christoph Garbers
SHSylvia Heink
Sylvia Heink
TKThomas Korn
Thomas Korn
SRStefan Rose-John
Stefan Rose-John

28 November 2016 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SHSylvia Heink
Sylvia Heink
NYNir Yogev
Nir Yogev
Christoph GarbersChristoph Garbers
Christoph Garbers
MHMarina Herwerth
Marina Herwerth
LALilian Aly
Lilian Aly
TKThomas Korn
Thomas Korn
Korn and colleagues report that Sirpα+ dendritic cells trans-present the cytokine IL-6 to T cells through a process that requires its receptor IL-6Rα bound to dendritic cells and that trans-presentation is needed to generate pathogenic cells of the TH17 subset of helper T cells in vivo. The cellular sources of interleukin 6 (IL-6) that are relevant for differentiation of the TH17 subset of helper T cells remain unclear. Here we used a novel strategy for the conditional deletion of distinct IL-6-producing cell types to show that dendritic cells (DCs) positive for the signaling regulator Sirpα were essential for the generation of pathogenic TH17 cells. Using their IL-6 receptor α-chain (IL-6Rα), Sirpα+ DCs trans-presented IL-6 to T cells during the process of cognate interaction. While ambient IL-6 was sufficient to suppress the induction of expression of the transcription factor Foxp3 in T cells, trans-presentation of IL-6 by DC-bound IL-6Rα (called 'IL-6 cluster signaling' here) was needed to prevent premature induction of interferon-γ (IFN-γ) expression in T cells and to generate pathogenic TH17 cells in vivo. Our findings should guide therapeutic approaches for the treatment of TH17-cell-mediated autoimmune diseases.

9 September 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
CFCaroline Fecher
Caroline Fecher
LTLaura Trovò
Laura Trovò
SMStephan Alexander Mueller
Stephan Alexander Mueller
NSNicolas Snaidero
Nicolas Snaidero
JWJennifer Wettmarshausen
Jennifer Wettmarshausen
TMThomas Misgeld
Thomas Misgeld

1 November 2014 in Immunity
Verified
Journal Article
Closed access
JVJ. Christoph Vahl
J. Christoph Vahl
CDChristoph Drees
Christoph Drees
KHKlaus Heger
Klaus Heger
SHSylvia Heink
Sylvia Heink
JFJulius C. Fischer
Julius C. Fischer
MSMarc Schmidt-Supprian
Marc Schmidt-Supprian

10 December 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MHMagdalena Huber
Magdalena Huber
SHSylvia Heink
Sylvia Heink
APAxel Pagenstecher
Axel Pagenstecher
KRKatharina Reinhard
Katharina Reinhard
JRJosephine Ritter
Josephine Ritter
MLMichael Lohoff
Michael Lohoff
IL-17–producing CD8+ T (Tc17) cells are detectible in multiple sclerosis (MS) lesions; however, their contribution to the disease is unknown. To identify functions of Tc17 cells, we induced EAE, a murine model of MS, in mice lacking IFN regulatory factor 4 (IRF4). IRF4-deficient mice failed to generate Tc17 and Th17 cells and were resistant to EAE. After adoptive transfer of WT CD8+ T cells and subsequent immunization for EAE induction in these mice, the CD8+ T cells developed a Tc17 phenotype in the periphery but could not infiltrate the CNS. Similarly, transfer of small numbers of WT CD4+ T cells alone did not evoke EAE, but when transferred together with CD8+ T cells, IL-17–producing CD4+ (Th17) T cells accumulated in the CNS and mice developed severe disease. Th17 accumulation and development of EAE required IL-17A production by CD8+ T cells, suggesting that Tc17 cells are required to promote CD4+ T cell–mediated induction of EAE. Accordingly, patients with early-stage MS harbored a greater number of Tc17 cells in the cerebrospinal fluid than in peripheral blood. Our results reveal that Tc17 cells contribute to the initiation of CNS autoimmunity in mice and humans by supporting Th17 cell pathogenicity.